GSK Drug Shows 19%-20% Hepatitis B Cure Rate In Late-Stage Trials

GSK said late-stage data showed bepirovirsen, its experimental drug, has strengthened the investment case around a key pipeline asset. The update is supportive for the company’s long-term biotech pipeline, though the article provides no detailed efficacy or safety figures yet. The tone is positive for GSK and likely modestly supportive for shares.

Analysis

GSK said late-stage data showed bepirovirsen, its experimental drug, has strengthened the investment case around a key pipeline asset. The update is supportive for the company’s long-term biotech pipeline, though the article provides no detailed efficacy or safety figures yet. The tone is positive for GSK and likely modestly supportive for shares.